

[ERS website](#) [Respiratory Channel](#) [ERS Publications](#)[Login](#)[0 items](#)

Search within ERS publications

[Journals](#)[Books](#)[Information for](#)[About us](#)[Topics](#)[Collections](#)

Conference Abstract

Cut-off of the Physical Performance Test to detect functional status impairment and mortality risk in interstitial lung disease

Cíntia Dias | Joana Antão | Cátia Paixão | Vânia Fernandes | Sérgio Campainha |
Chris Burtin | Alda Marques [See Less](#)

European Respiratory Journal 2025 66(suppl 69): PA674; DOI:
<https://doi.org/10.1183/13993003.congress-2025.PA674>



This article appears in:

European Respiratory Journal
Vol 66 Issue suppl 69

[Permissions](#)[Add to Favourites](#)[Labels](#)[Cite](#)[Share](#)[Alerts](#)

[Article](#)[Figures & Tables](#)[Info & Metrics](#)

Abstract

Functional status (FS) is a key outcome in people with interstitial lung disease (ILD). Physical Performance Test (PPT) is a FS measure. However, cut-off points to determine FS impairment and mortality risk as estimated by the 6-minute walk test (6MWT) with the PPT in people with ILD are lacking. This study explored thresholds of PPT to identify FS impairment and mortality risk in people with ILD.

A cross-sectional study was conducted. FS was assessed with the PPT, short (PPT-28) and long (PPT-36) versions. FS impairment was defined as a 6MWT of less than 70% of the predicted value. Cut-offs of 6MWT for mortality risk (250, 330 and 350m) were also explored. Optimal cut-off values were determined based on the highest Youden index in receiver operating characteristic (ROC) analysis.

85 people with ILD were included (68 ± 11 years; 53% male; FVC_{pp} 81 ± 22 ; DLCO_{pp} 57 ± 21). A cut-off of <19.5 for PPT-28 identified FS impairment and mortality risk across all 6MWT cut-offs. For PPT-36, a cut-off of <28.5 detected FS impairment, while <27.5 ($6\text{MWT} < 350\text{m}$) and <26.5 ($6\text{MWT} < 330\text{m}$ and $<250\text{m}$) identified mortality risk.

In ILD, cut-off values of <19.5 for PPT-28 and <28.5 and <26.5 for PPT-36 may be used to detect FS impairment and mortality risk as estimated by the 6MWT, respectively. This information can now be used to provide tailored interventions.

		Gold standard	Cut-off	AUC (95%CI)	Sensitivity	Specificity	
PPT-28	Functional impairment	6MWT \leq 70%	19.5	0.759 (0.613-0.905)	81.7%	54.5%	
	Risk of mortality	6MWT<250m	19.5	0.846 (0.669-1.022)	82.7%	85.7%	
		6MWT<330m	19.5	0.761 (0.597-0.924)	83.1%	63.6%	
		6MWT<350m	19.5	0.764 (0.613-0.914)	82.9%	58.3%	
	Functional impairment	6MWT \leq 70%	28.5	0.850 (0.741-0.958)	67.6%	90.9%	
	Risk of mortality	6MWT<250m	26.5	0.952 (0.903-1.002)	84.0%	100.0%	
PPT-36		6MWT<330m	26.5	0.855 (0.727-0.982)	85.5%	72.7%	
		6MWT<350m	27.5	0.850 (0.731-0.969)	72.9%	83.3%	
Functional impairment	6MWT \leq 70%	28.5	0.850 (0.741-0.958)	67.6%	90.9%		
Risk of mortality	6MWT<250m	26.5	0.952 (0.903-1.002)	84.0%	100.0%		
	6MWT<330m	26.5	0.855 (0.727-0.982)	85.5%	72.7%		
	6MWT<350m	27.5	0.850 (0.731-0.969)	72.9%	83.3%		

Figure 1- Cut-offs of the physical performance test (PPT), PPT-28 (7 tasks) and PPT-36 (9 tasks) versions to detect functional status impairment based on the cut-off of 70% predicted of the six-minute walk test – 6MWT (6MWT \leq 70%) and mortality risk based on cut-offs of the 6MWT of 250m, 330m and 350m, in people with interstitial lung disease. The respective areas under the curve (AUC) and 95% Confidence Intervals (95% CI), sensitivity and specificity are shown.

Footnotes

Cite this article as *Eur Respir J* 2025; 66: Suppl. 69, PA674.

This article was presented at the 2025 ERS Congress, in session “Advances in exercise testing for respiratory disease”.

This is an ERS Congress abstract. No full-text version is available. Related materials (such as slides or recordings) will be accessible via the ERS Respiratory Channel at <https://channel.ersnet.org/programme-live-418>

 Focus  Previous  Next 

We recommend

Right ventricular dysfunction and functional limitation in idiopathic pulmonary fibrosis.

The impact of disease severity measures on survival in U.S. Veterans with rheumatoid arthritis-associated interstitial lung disease 